초록 ▼

The invention relates to an apparatus comprising a closure-cap and a container in the form of a two-chamber cartridge in which an active ingredient and a solvent can be stored separately until the apparatus is used in a nebulizer, as well as an active substance concentrate in which the active-substa

The invention relates to an apparatus comprising a closure-cap and a container in the form of a two-chamber cartridge in which an active ingredient and a solvent can be stored separately until the apparatus is used in a nebulizer, as well as an active substance concentrate in which the active-substance is present as a solution or suspension for storage purposes.

대표청구항 ▼

The invention claimed is: 1. An apparatus comprising: a container; and a closure-cap having: (i) a guide tube for passage of a capillary or cannula through the closure-cap, (ii) a connecting piece which at least partially enters the container through an upper edge of the container's neck when the c

The invention claimed is: 1. An apparatus comprising: a container; and a closure-cap having: (i) a guide tube for passage of a capillary or cannula through the closure-cap, (ii) a connecting piece which at least partially enters the container through an upper edge of the container's neck when the closure-cap is pushed onto the neck, (iii) a chamber integral within the connecting piece and including at least one opening, and (iv) a plunger disposed downward from the upper edge of the neck within the chamber and sealing the at least one opening thereof, the plunger including at least three sides defining a hollow space to hold one of a pharmaceutical concentrate and a pharmacologically acceptable liquid, and at least one aperture that is sealed when the plunger is in a first position and that opens when the plunger is in a second position, wherein: the pharmaceutical concentrate includes one or more active ingredients, selected from the group consisting of: betamimetics, anticholinergics, antiallergics, leukotriene antagonists and/or steroids, in a pharmacologically acceptable propellant-free liquid, a pharmaceutical formulation is formed in response to the plunger being in the second position and the pharmaceutical concentrate and the pharmacologically acceptable liquid combine. 2. The apparatus of claim 1, wherein the pharmaceutical formulation has a concentration of the active ingredient of at least one of: between about 0.001 to 5.0% by weight and between about 0.05 and 3.0% by weight. 3. The apparatus of claim 1, wherein an active ingredient of the pharmaceutical concentrate includes tiotropium bromide. 4. The apparatus of claim 3, wherein an amount of tiotropium bromide in the pharmaceutical formulation is at least one of: between about 0.002 and about 0.4% by weight; between about 0.0005 and about 0.2% by weight; about 0.1% by weight. 5. The apparatus of claim 4, wherein the pharmaceutical formulation has a pH of at least one of: about 2.0 to 4.0; about 2.0 to 3. 0; and about 2.8. 6. The apparatus of claim 1, wherein at least one of: a concentration of the one or more active ingredients of the pharmaceutical concentrate is between about 75 mg/ml and about 1000 mg/ml; the concentration of the one or more active ingredients of the pharmaceutical concentrate is between about 75 mg/ml and about 500 mg/ml; the concentration of the one or more active ingredients of the pharmaceutical concentrate is between about 100 mg/ml and about 400 mg/ml; the concentration of the one or more active ingredients of the pharmaceutical concentrate is between about 75 mg/ml and about 200 mg/ml; and the concentration of the one or more active ingredients of the pharmaceutical concentrate is between about 75 mg/ml and about 150 mg/ml. 7. The apparatus of claim 1, wherein the pharmaceutical concentrate is in the form of a suspension or a solution. 8. The apparatus of claim 1, wherein the pharmaceutical concentrate contains a co-solvent and/or other pharmacologically acceptable excipients or additives selected from the group consisting of surfactants, stabilizers, complexing agents, antioxidants and/or preservatives, which prolong the duration of use of the finished pharmaceutical formulation, flavourings and/or vitamins. 9. The apparatus of claim 8, wherein the pharmaceutical concentrate contains an inorganic or organic acid as the stabilizer. 10. The apparatus of claim 1, wherein a pH-value of the pharmaceutical concentrate is between about 2.0 and 7.0. 11. The apparatus of claim 1, wherein the pharmacologically acceptable propellant-free liquid is a polar liquid or a protic liquid. 12. The apparatus of claim 1, wherein the pharmacologically acceptable propellant-free liquid is water, an aqueous solution with a pharmacologically acceptable salt, ethanol or a mixture thereof. 13. The apparatus of claim 12, wherein the pharmacologically acceptable propellant-free liquid is a saline solution with a salt content of up to about 50% by weight, or up to about 20% by weight. 14. An apparatus comprising: a container having a neck leading to a volume for storing a pharmacologically acceptable liquid; a closure cap including: (i) a connecting piece which at least partially enters the volume through the neck when the closure-cap engages the container, (ii) a chamber integral within the connecting piece and including at least one opening at a lower end thereof, the chamber including a pharmaceutical concentrate including one or more active ingredients, selected from the group consisting of: betamimetics, anticholinergics, antiallergics, leukotriene antagonists and/or steroids, in a pharmacologically acceptable propellant-free liquid; and (iii) a guide tube extending through the closure cap to an upper end of the chamber; a plunger disposed downward from the neck and sealing an upper end of the chamber when in a first position, the plunger being movable by inserting a device through the guide tube; and a separating element sealing the opening at the lower end of the chamber, wherein movement of the plunger from the first position to a second position toward the lower end of the chamber breaks the seal by the separating element and permits the pharmaceutical concentrate to exit the chamber and combine with the pharmacologically acceptable liquid to form a pharmaceutical formulation in the volume of the container. 15. The apparatus of claim 14, wherein the pharmaceutical formulation has a concentration of the active ingredient of at least one of: between about 0.001 to 5.0% by weight and between about 0.05 and 3.0% by weight. 16. The apparatus of claim 14, wherein an active ingredient of the pharmaceutical concentrate includes tiotropium bromide. 17. The apparatus of claim 16, wherein an amount of tiotropium bromide in the pharmaceutical formulation is at least one of: between about 0.002 and about 0.4% by weight; between about 0.0005 and about 0.2% by weight; about 0.1% by weight. 18. The apparatus of claim 17, wherein the pharmaceutical formulation has a pH of at least one of: about 2.0 to 4.0; about 2.0 to 3. 0; and about 2.8. 19. The apparatus of claim 14, wherein at least one of: a concentration of the one or more active ingredients of the pharmaceutical concentrate is between about 75 mg/ml and about 1000 mg/ml; the concentration of the one or more active ingredients of the pharmaceutical concentrate is between about 75 mg/ml and about 500 mg/ml; the concentration of the one or more active ingredients of the pharmaceutical concentrate is between about 100 mg/ml and about 400 mg/ml; the concentration of the one or more active ingredients of the pharmaceutical concentrate is between about 75 mg/ml and about 200 mg/ml; and the concentration of the one or more active ingredients of the pharmaceutical concentrate is between about 75 mg/ml and about 150 mg/ml. 20. The apparatus of claim 14, wherein the pharmaceutical concentrate is in the form of a suspension or a solution. 21. The apparatus of claim 14, wherein the pharmaceutical concentrate contains a co-solvent and/or other pharmacologically acceptable excipients or additives selected from the group consisting of surfactants, stabilizers, complexing agents, antioxidants and/or preservatives, which prolong the duration of use of the finished pharmaceutical formulation, flavourings and/or vitamins. 22. The apparatus of claim 21, wherein the pharmaceutical concentrate contains an inorganic or organic acid as the stabilizer. 23. The apparatus of claim 14, wherein a pH-value of the pharmaceutical concentrate is between about 2.0 and 7.0. 24. The apparatus of claim 14, wherein the pharmacologically acceptable propellant-free liquid is a polar liquid or a protic liquid. 25. The apparatus of claim 14, wherein the pharmacologically acceptable propellant-free liquid is water, an aqueous solution with a pharmacologically acceptable salt, ethanol or a mixture thereof. 26. The apparatus of claim 25, wherein the pharmacologically acceptable propellant-free liquid is a saline solution with a salt content of up to about 50% by weight, or up to about 20% by weight.